CN112888446A - 操纵免疫细胞中的arid5b表达以促进代谢、存活和功能 - Google Patents

操纵免疫细胞中的arid5b表达以促进代谢、存活和功能 Download PDF

Info

Publication number
CN112888446A
CN112888446A CN201980046610.6A CN201980046610A CN112888446A CN 112888446 A CN112888446 A CN 112888446A CN 201980046610 A CN201980046610 A CN 201980046610A CN 112888446 A CN112888446 A CN 112888446A
Authority
CN
China
Prior art keywords
cells
cell
arid5b
immune cells
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980046610.6A
Other languages
English (en)
Chinese (zh)
Inventor
杰弗里·史蒂文·米勒
弗兰克·马丁·齐霍茨基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota System
Original Assignee
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota System filed Critical University of Minnesota System
Publication of CN112888446A publication Critical patent/CN112888446A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201980046610.6A 2018-05-14 2019-05-08 操纵免疫细胞中的arid5b表达以促进代谢、存活和功能 Pending CN112888446A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862670962P 2018-05-14 2018-05-14
US62/670,962 2018-05-14
PCT/US2019/031296 WO2019221991A1 (en) 2018-05-14 2019-05-08 Manipulating arid5b expression in immune cells to promote metabolism, survival, and function

Publications (1)

Publication Number Publication Date
CN112888446A true CN112888446A (zh) 2021-06-01

Family

ID=68540927

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980046610.6A Pending CN112888446A (zh) 2018-05-14 2019-05-08 操纵免疫细胞中的arid5b表达以促进代谢、存活和功能

Country Status (7)

Country Link
US (1) US12109236B2 (cg-RX-API-DMAC7.html)
EP (1) EP3793574A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021523717A (cg-RX-API-DMAC7.html)
CN (1) CN112888446A (cg-RX-API-DMAC7.html)
AU (1) AU2019269318A1 (cg-RX-API-DMAC7.html)
CA (1) CA3100312A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019221991A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7793517B2 (ja) * 2019-11-28 2026-01-05 アムニオティクス・アーベー ソース細胞から決定的造血細胞を生成する方法
CN111733154B (zh) * 2020-04-30 2022-11-04 和也健康科技有限公司 磁场处理的免疫细胞及其用途
KR20230042671A (ko) * 2020-05-28 2023-03-29 바이오마그네틱 솔루션스 엘엘씨 단일 항체를 이용한 나이브 t 및 b 세포의 음성 선택을 위한 조성물 및 방법
EP4419541A4 (en) * 2021-10-21 2025-12-17 Univ Texas METHOD FOR PRODUCING THERAPEUTIC IMMUNE CELLS WITH IMPROVED METABOLIC FITNESS AND COMPOSITIONS THEREOFUL

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017048809A1 (en) * 2015-09-14 2017-03-23 Regents Of The University Of Minnesota Nk cells exhibiting an adaptive phenotype and methods for preparing and for using

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837492A (en) 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
US6448717B1 (en) 2000-07-17 2002-09-10 Micron Technology, Inc. Method and apparatuses for providing uniform electron beams from field emission displays
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US20180371052A1 (en) 2015-12-22 2018-12-27 Icell Gene Therapeutics Llc Chimeric antigen receptors and enhancement of anti-tumor activity
EP3452580B1 (en) 2016-05-02 2023-08-16 Cerus Corporation Compositions and methods for improved nk cell therapies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017048809A1 (en) * 2015-09-14 2017-03-23 Regents Of The University Of Minnesota Nk cells exhibiting an adaptive phenotype and methods for preparing and for using

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
WEI ZHONG LEONG ET AL: "ARID5B as a critical downstream target of the TAL1 complex that activates the oncogenic transcriptional program and promotes T-cell leukemogenesis", 《GENES & DEVELOPMENT》 *
YONGMEI LIU ET AL: "Blood monocyte transcriptome and epigenome analyses reveal loci associated with human atherosclerosis", 《NAT COMMUN》 *
钱锡峰等: "ARID5B基因与儿童急性淋巴细胞白血病关联性的研究进展", 《中国实验血液学杂志》 *

Also Published As

Publication number Publication date
US20210154232A1 (en) 2021-05-27
AU2019269318A1 (en) 2021-01-07
JP2021523717A (ja) 2021-09-09
EP3793574A4 (en) 2022-03-09
EP3793574A1 (en) 2021-03-24
WO2019221991A1 (en) 2019-11-21
CA3100312A1 (en) 2019-11-21
US12109236B2 (en) 2024-10-08

Similar Documents

Publication Publication Date Title
Chen et al. Induction of myelodysplasia by myeloid-derived suppressor cells
Tsoi et al. Lats1 and Lats2 are required for ovarian granulosa cell fate maintenance
EP3374497B1 (en) Modified macrophages for use in the treatment of cancer
Jia et al. Hyperactive PI3Kδ predisposes naive T cells to activation via aerobic glycolysis programs
US12109236B2 (en) Manipulating ARID5B expression in immune cells to promote metabolism, survival, and function
EP2757157A1 (en) Modulation of mitophagy and use thereof
WO2015003149A2 (en) Soluble cd33 for treating myelodysplastic syndromes (mds)
Jackson et al. The Haematopoietically-expressed homeobox transcription factor: roles in development, physiology and disease
Ellert-Miklaszewska et al. 7aaRGD-a novel SPP1/integrin signaling-blocking peptide reverses immunosuppression and improves anti-PD-1 immunotherapy outcomes in experimental gliomas
WO2018174984A1 (en) Low-density lipoprotein receptor related protein 5 inhibition suppresses tumor formation
EP2970975A1 (en) Targeting chromatin modifiers for the treatment of medical conditions
US9091696B2 (en) Modulation of NR2F6 and methods and uses thereof
Won et al. A new triggering receptor expressed on myeloid cells (TREM) family member, TLT-6, is involved in activation and proliferation of macrophages
HK40044945A (en) Manipulating arid5b expression in immune cells to promote metabolism, survival, and function
US20110301110A1 (en) TRIM33 (TIF1gamma) AS A NEW DIAGNOSTIC MARKER OF CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
WO2015054477A1 (en) Methods of diagnosing and treating b cell acute lymphoblastic leukemia
CN107073079A (zh) 包括给予PPAR‑γ激动剂的治疗癌症的方法
Kouskoff et al. Editors' Showcase 2021: Insights in Stem Cell Research
Jin et al. One infusion of engineered long-lasting and multifunctional T cells cures asthma in mice
Gao et al. Targeting CAR-T cell senescence through Mysm1-SSBP1 axis improves persistence and therapeutic efficacy
Gray Hedgehog signaling in Triple-Negative Breast Cancer: Effects on the Tumor Immune Microenvironment
Swoboda Characterization of CSF3R Mutations in Core Binding Factor Leukemia
Lazarov Developmental Origins of Tissue Macrophages and Their Potential Role in Lupus Pathogenesis
Horwitz Uncovering key determinants of skeletal muscle repair
RU2775674C2 (ru) Способы иммунотерапии и композиции, включающие модуляторы метаболического пути триптофана

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40044945

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210601